Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
65 hedge funds and large institutions have $194M invested in Mersana Therapeutics in 2019 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 26 increasing their positions, 9 reducing their positions, and 4 closing their positions.
425% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 4
189% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 9
177% more capital invested
Capital invested by funds: $70M → $194M (+$124M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
35% more funds holding
Funds holding: 48 → 65 (+17)
0.14% more ownership
Funds ownership: 2.96% → 3.1% (+0.14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$18.9M |
| 2 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$18.9M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$12.6M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$11.6M |
| 5 |
O
OrbiMed
New York
|
+$9.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$1.45M |
| 2 |
JG
Jefferies Group
New York
|
-$1.37M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$158K |
| 4 |
Morgan Stanley
New York
|
-$63.3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$47.2K |
MRSN Hedge Fund Activity: Q1 2019 in Review
65 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q1 2019, worth a combined $194M — up 177% from $70M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new MRSN positions and 4 closed out — a net gain of 17 holders — while 26 added to existing stakes and 9 trimmed.
The largest buyer was NEA Management Company, adding an estimated $18.9M. The largest seller was Fidelity International, exiting entirely with an estimated $1.45M sold.
- 65 institutional investors held Mersana Therapeutics (MRSN) as of Q1 2019, up from 48 in Q4 2018.
- Funds reported $194M of Mersana Therapeutics stock for Q1 2019, up 177% quarter-over-quarter.
- 21 funds opened new Mersana Therapeutics positions in Q1 2019 and 4 closed out, a net change of +17 holders.
- The largest Mersana Therapeutics buyer in Q1 2019 was NEA Management Company, an estimated $18.9M added.
- The largest Mersana Therapeutics seller in Q1 2019 was Fidelity International, an estimated $1.45M sold.
Based on aggregated 13F filings for Q1 2019.